Envestnet Asset Management Inc. Buys 4,449 Shares of Teleflex Incorporated $TFX

Envestnet Asset Management Inc. lifted its stake in shares of Teleflex Incorporated (NYSE:TFX) by 13.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 36,511 shares of the medical technology company’s stock after acquiring an additional 4,449 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.08% of Teleflex worth $4,467,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in Teleflex by 23.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 83,388 shares of the medical technology company’s stock worth $9,870,000 after buying an additional 15,935 shares during the period. Speece Thorson Capital Group Inc. lifted its position in shares of Teleflex by 2.4% in the second quarter. Speece Thorson Capital Group Inc. now owns 89,843 shares of the medical technology company’s stock valued at $10,634,000 after acquiring an additional 2,096 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Teleflex by 113.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 58,047 shares of the medical technology company’s stock worth $7,366,000 after acquiring an additional 30,912 shares during the period. Creative Planning grew its position in shares of Teleflex by 76.5% during the second quarter. Creative Planning now owns 10,338 shares of the medical technology company’s stock worth $1,224,000 after purchasing an additional 4,480 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its stake in Teleflex by 31.5% during the 2nd quarter. Teacher Retirement System of Texas now owns 11,819 shares of the medical technology company’s stock valued at $1,399,000 after purchasing an additional 2,831 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on TFX shares. Wells Fargo & Company dropped their price target on Teleflex from $139.00 to $116.00 and set an “equal weight” rating for the company in a research note on Thursday, January 29th. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a report on Monday, December 29th. Needham & Company LLC raised shares of Teleflex from a “hold” rating to a “buy” rating and set a $138.00 target price for the company in a research note on Tuesday, January 27th. Wall Street Zen downgraded shares of Teleflex from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $135.00 price objective on shares of Teleflex in a report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $139.00.

Teleflex Trading Down 2.1%

TFX opened at $113.02 on Tuesday. The stock has a 50-day moving average of $111.96 and a 200 day moving average of $118.77. The company has a current ratio of 2.57, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. Teleflex Incorporated has a 12 month low of $100.18 and a 12 month high of $180.58. The firm has a market cap of $4.99 billion, a P/E ratio of -15.38, a P/E/G ratio of 1.50 and a beta of 0.92.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.